GovWire

Consultation outcome: Standard adult ready-to-drink oral nutritional supplements: ACBS policy

Department Of Health

August 22
08:30 2024

The consultation proposed a change to adultoral nutritional supplement volume size, and most people agreed it would improve prescribing and reduce errors.

However,the Advisory Committee on Borderline Substances (ACBS)is not recommending action on volume size at this time because responses raised several other important concerns that need to be explored first.

Patient safety incidents were reported andACBSis proposing an audit to determine the scale and nature of incidents. NHS England and the Optimising Nutrition Prescribing Specialist Group of the British Dietetic Association have agreed to undertake this work and report the outcomes.

Following this,ACBSand others will commence dialogue with industry about any problems identified and reported with packaging, labelling and product names.ACBSwill then decide whether to advise on changes.

Separately,ACBSwill work with stakeholders to improve communication of prescribing practice. Work by theNHS Business Services Authorityto categorise nutritional borderline substances has laid the foundation to replicate this in theBritish National Formularyand ensure consistency across the system.


Original consultation

Summary

We want your views on changes being proposed to Advisory Committee on Borderline Substances (ACBS) policy about standard adult ready-to-drink oral nutritional supplements listed in part XV of the Drug Tariff.

This consultation ran from
to

Consultation description

The proposed changes cover:

  • the standardising of pack sizes to 125ml and 200ml
  • the listing of no more than one volume of each product
  • the recommending of 1kcal/ml ONS for certain clinical conditions only
  • criteria for standard adult ready-to-drink oral nutritional supplements prescribed for use once per day
  • the use of complete and fibre in brand names and when describing products

Documents

Related Articles

Comments

  1. We don't have any comments for this article yet. Why not join in and start a discussion.

Write a Comment

Your name:
Your email:
Comments:

Post my comment

Recent Comments

Follow Us on Twitter

Share This


Enjoyed this? Why not share it with others if you've found it useful by using one of the tools below: